ARN-509: a novel anti-androgen for prostate cancer treatment

Continued reliance on the androgen receptor (AR) is now understood as a core mechanism in castration-resistant prostate cancer (CRPC), the most advanced form of this disease. While established and novel AR-pathway targeting agents display clinical efficacy in metastatic CRPC, dose-limiting side effe...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Clegg, Nicola J., Wongvipat, John, Joseph, Jim, Tran, Chris, Ouk, Samedy, Dilhas, Anna, Chen, Yu, Grillot, Kate, Bischoff, Eric D., Cai, Ling, Aparicio, Anna, Dorow, Steven, Arora, Vivek, Shao, Gang, Qian, Jing, Zhao, Hong, Yang, Guangbin, Cao, Chunyan, Sensintaffar, John, Wasielewska, Teresa, Herbert, Mark R., Bonnefous, Celine, Darimont, Beatrice, Scher, Howard I., Smith-Jones, Peter, Klang, Mark, Smith, Nicholas D., De Stanchina, Elisa, Wu, Nian, Ouerfelli, Ouathek, Rix, Peter J., Heyman, Richard A., Jung, Michael E., Sawyers, Charles L., Hager, Jeffrey H.
Format: Artigo
Jezik:Inglês
Izdano: 2012
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3306502/
https://ncbi.nlm.nih.gov/pubmed/22266222
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-11-3948
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki